Anaerobic exercise uses glucose for energy, instead of oxygen. Aerobic (cardio) and anaerobic exercises both improve health, but only anaerobic exercises build muscle mass and strength. Anaerobic ...

Discover Vor BiopharmaVor Biopharma Inc.'s potential with telitacicept amid funding challenges and market risks. Click for ...

Vor Biopharma ( ($VOR) ) has provided an announcement. On December 5, 2025, Vor Biopharma‘s board approved a stock option repricing, reducing the ...

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the ...

I created Be Attractive because I wanted one simple, natural supplement to help me look my best. After diving into the research, I found that most products were underdosed, used poor quality and cheap ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

VOR pivoted from cell therapy to in-licensing telitacicept, securing $175M in private placement but at the cost of massive dilution. Telitacicept offers multi-billion market potential if global trials ...

Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...

(RTTNews) - Vor Bio (VOR) and RemeGen Co. announced entry into a license agreement granting Vor Bio global rights excluding China, Hong Kong, Macau and Taiwan to develop and commercialize telitacicept ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis ...